Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Curevac N.V. (NQ: CVAC )

3.360 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 502,032
Open 3.340
Bid (Size) 3.380 (1)
Ask (Size) 3.400 (5)
Prev. Close 3.360
Today's Range 3.230 - 3.400
52wk Range 2.215 - 11.49
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CureVac Announces Voting Results of General Meeting
Via ACCESSWIRE
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga

Performance

YTD
-19.81%
-19.81%
1 Month
-8.45%
-8.45%
3 Month
+10.89%
+10.89%
6 Month
-21.50%
-21.50%
1 Year
-70.03%
-70.03%

More News

Read More
First Human Death From Bird Flu Strain Puts Vaccine Stocks Back On The Map
Via Benzinga
Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
Via ACCESSWIRE
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
Via ACCESSWIRE
Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday
Via Benzinga
CVAC Stock Earnings: CureVac Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
3 Stocks to Purge ASAP Before They’re Pulled off Life Support
Via InvestorPlace
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Via Benzinga
Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday
Via Benzinga
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
Via ACCESSWIRE
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
Via ACCESSWIRE
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Via ACCESSWIRE
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
Via ACCESSWIRE
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
Via ACCESSWIRE
Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert
Via Benzinga
CureVac, GS Partner Release Data On Influenza Vaccine Study
Via Benzinga
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Via ACCESSWIRE
Why Biopharmaceutical Player CureVac Shares Are Rising Today
Via Benzinga
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.